Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 3Breast 2Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Receptor Protein-Tyrosine Kinases × CNS × Clear all
NCT01753713 2017-12-12

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Case Comprehensive Cancer Center

Phase 2 Completed
33 enrolled 14 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡